Latest development in viral vectors for gene therapy

Trends in Biotechnology

Volumn 21, Issue 3, 2003, Pages 117-122

  Lundstrom, Kenneth ^a  

^a BioXtal   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; GENES; VECTORS; VIRUSES;

HEREDITARY DISEASES;

BIOTECHNOLOGY;

VIRUS VECTOR;

VIRUS;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ALPHA VIRUS; DEVELOPMENT; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; GENOME; HERPES SIMPLEX VIRUS; LENTIVIRINAE; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; REVIEW; TRANSGENE;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ALPHAVIRUS; LENTIVIRUS; MAMMALIA; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0037333336     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(02)00042-2     Document Type: Review

References (43)

1. Cavazzana-Calvo M., et al. Gene therapy of human severe combined immune deficiency (SCID)-X1 disease. Science. 288:2000;669-672.
2. Raper S.E., et al. A pilot study of in vivo liver-directed gene transfer with an Adenoviral vector in partial ornitine transcarbamylase deficiency. Hum. Gene Ther. 13:2002;163-175.
3. Check E. Gene therapy: a tragic setback. Nature. 420:2002;116-118.
4. Dettweiler U., Simon P. Points to consider for ethics committees in human gene therapy trials. Bioethics. 15:2001;491-500.
5. Rabinowtz J.E., Samulski J. Adeno-associated virus expression systems for gene transfer. Curr. Opin. Biotechnol. 9:1998;470-475.
6. Davidson B.L., et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. U. S. A. 97:2000;3428-3432.
7. Gao G.-P., et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99:2002;11854-11859.
8. Auricchio A., et al. Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol. Ther. 6:2002;238-242.
9. Duverger V., et al. Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2. Int. J. Cancer. 97:2002;706-712.
10. Schiedner G., et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 18:1998;180-183.
11. Stecher H., et al. A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells. Mol. Ther. 4:2001;36-44.
12. Haviv Y.S., et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res. 62:2002;4273-4281.
13. Fisher K.D., et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 8:2001;341-348.
14. Croyle M.A., et al. PEGylation of E1-deleted Adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther. 13:2002;1887-1900.
15. Lieber A., et al. Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes. J. Virol. 73:1999;9314-9324.
16. Lundstrom K. Alphavirus vectors for gene therapy applications. Curr. Gene Ther. 1:2001;19-29.
17. Lundstrom K. Alphavirus-based vaccines. Curr. Opin. Mol. Ther. 4:2002;28-34.
18. Asselin-Paturel C., et al. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther. 6:1999;606-615.
19. Murphy A.-M., et al. Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles. Gene Ther. 7:2000;1477-1482.
20. Yamanaka R., et al. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J. Neurosurg. 97:2002;611-618.
21. Cheng W.-F., et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum. Gene Ther. 13:2002;553-568.
22. Ohno K., et al. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat. Biotechnol. 15:1997;763-767.
23. Lundstrom, K. and Boulikas, T. Breakthrough in cancer therapy: encapsulation of drugs and viruses. Curr. Drug Disc. (in press).
24. Samaniego L.A., et al. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J. Virol. 72:1998;3307-3320.
25. Goins W.F., et al. A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. J. Virol. 68:1994;2239-2252.
26. Wilson S.P., et al. Antihypergelsic effects of infection with a preproenkephalin-encoding herpes simplex virus. Proc. Natl. Acad. Sci. U. S. A. 96:1999;3211-3216.
27. Krisky D.M., et al. Deletion of immediate early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther. 5:1998;1593-1603.
28. Harland J., et al. HSV1716 persistence in primary human glioma cells in vitro. Gene Ther. 9:2002;1194-1198.
29. Niranjan A., et al. Effective treatment of experimental glioblastoma by herpes simplex virus type-1 vector-mediated TNFalpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol. Ther. 2:2000;114-120.
30. Akkaraju G.R., et al. Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle. J. Gene Med. 1:1999;280-289.
31. + cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model. Gene Ther. 7:2000;43-52.
32. Burns J.C., et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8033-8037.
33. Hu W.-S., Pathak V.K. Design of retroviral vectors and helper cells for gene therapy. Pharmacol. Rev. 52:2000;493-511.
34. Khare P.D., et al. Tumor growth suppression by a retroviral vector displaying scFv antibody to CEA and carrying the iNOS gene. Anticancer Res. 22:2002;2443-2446.
35. Blaese R.M., et al. T-lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 270:1995;475-480.
36. Bonini C., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 276:1997;1719-1724.
37. Vigna E., Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J. Gene Med. 2:2000;308-316.
38. Kay M.A., et al. Viral vectors for gene therapy: the art of turning infectious agents into vehicles for therapeutics. Nat. Med. 7:2001;33-40.
39. Follenzi A., et al. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum. Gene Ther. 13:2002;243-260.
40. Ikeda Y., et al. Gene transduction efficiency in cells of different species by HIV and EIAV. Gene Ther. 9:2002;932-938.
41. Paddison P.J., et al. Stable suppression of gene expression by RNAi in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 99:2002;1443-1448.
42. McManus M.T., Sharp P.A. Gene silencing in mammalis by small interfering RNAs. Nat. Rev. 3:2002;737-747.
43. Xia H., et al. siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 20:2002;1006-1010.